Last updated: February 26, 2026
What Is the Drug Under NDC 51407-0265?
The National Drug Code (NDC) 51407-0265 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), developed by Novartis. It is an adeno-associated virus vector-based gene therapy approved by the FDA in May 2019 for treating spinal muscular atrophy (SMA) in pediatric patients.
Market Size and Demand Dynamics
Prevalence of Spinal Muscular Atrophy
- SMA affects approximately 1 in 11,000 live births globally.
- Estimated US prevalence: 9,000 to 10,000 patients, with roughly 350 new cases annually.
- The subset eligible for Zolgensma typically includes infants with SMA Type 1.
Treatment Landscape
- Before Zolgensma, disease management involved supportive care and alternative therapies such as Spinraza (nusinersen) and Evrysdi (risdiplam).
- The introduction of Zolgensma offers a one-time gene therapy option, creating a new treatment paradigm.
Market Penetration and Adoption
Regulatory Approvals and Availability
- Approved by FDA (2019), EMA (2020), and other global agencies.
- Coverage policies vary; early adoption limited by pricing and reimbursement negotiations.
Competition Analysis
| Therapy |
Type |
Approval Year |
Course |
Price (USD) |
Market Share (2022 Estimated) |
| Zolgensma |
Gene therapy |
2019 |
Single infusion |
2.1 million |
~60% |
| Spinraza |
mRNA antisense oligonucleotide |
2016 |
Lifetime |
750,000 |
~35% |
| Evrysdi |
RNA splicing modifier |
2020 |
Monthly injections |
340,000/year |
~5% |
Price Setting and Reimbursement
- List Price: US$2.125 million per dose.
- Cost per Patient: Varies based on reimbursement negotiations; actual paid amounts often lower.
- Reimbursement Challenges: High upfront cost prompts payer resistance, with some insurers requiring outcomes-based agreements.
Price Trends and Forecasts
Historical Price Trends
- The initial list price set at approximately $2.125 million in 2019.
- Price reductions observed in negotiated payor contracts, with discounts ranging from 10% to 30% in some cases.
- No significant price reductions publicly reported but potential for future discounts driven by market competition and value-based agreements.
Short to Medium Term Price Projections (2023-2028)
| Year |
Expected Price Range (USD) |
Drivers |
| 2023 |
$1.9 million – $2.2 million |
Negotiation pressure, manufacturer discounts |
| 2024 |
$1.8 million – $2.1 million |
Payer cost containment, expanded access programs |
| 2025 |
$1.7 million – $2 million |
Competitive pressures, biosimilar entry potential |
| 2026-2028 |
Stabilization around $1.6 million – $1.8 million |
Market saturation, value assessments |
Key factors influencing price projections
- Payer negotiations: Payers demand outcomes-based agreements or price discounts.
- Market competition: Entry of emerging therapies or biosimilars could depress prices.
- Manufacturing costs: Stable, but possible reduction with process improvements.
- Regulatory and policy shifts: US and global negotiations on drug pricing, especially within value-based frameworks.
Market Opportunities and Risks
Opportunities
- Expanding indications for older SMA populations.
- Broader global approval, especially in emerging markets.
- Strategic partnerships and expanded access programs.
Risks
- Payer resistance to high upfront costs.
- Development of competing gene therapies or alternative delivery platforms.
- Price caps under legislative or health policy reforms.
Key Takeaways
- Zolgensma remains the most expensive gene therapy in the world, with a list price of approximately US$2.125 million per dose.
- Market demand remains high among eligible infant SMA patients, but access is limited by reimbursement issues.
- Future price declines are probable, driven by negotiations, competitive entries, and policy shifts.
- The overall market is expected to stabilize around a price range of US$1.6 million to US$2 million over the next five years.
- Market growth depends on expanding indications and global adoption; risks include pricing pressures and regulatory constraints.
FAQs
Q1: How does Zolgensma compare price-wise to other gene therapies?
A1: It is significantly more expensive than other gene therapies, with its list price exceeding US$2 million, positioned as the highest-priced medicine worldwide.
Q2: What factors influence reimbursement for Zolgensma?
A2: Reimbursement depends on negotiations with payers, health economic evaluations, outcomes-based agreements, and policy environments.
Q3: Are there biosimilar or generic alternatives to Zolgensma?
A3: No biosimilar or generic versions exist as of 2023, but biosimilar development could affect pricing in the future.
Q4: How will the global approval landscape affect prices?
A4: Broader approvals could increase access, but pricing negotiations will vary by country, affecting realized prices.
Q5: What is the potential for price reductions due to competition?
A5: Entry of competitors and biosimilars could prompt significant price reductions, especially beyond 2025.
References
[1] Food and Drug Administration. (2019). FDA approves novel gene therapy to treat infants with spinal muscular atrophy. https://www.fda.gov/news-events/press-announcements/fda-approves-novels-gene-therapy-treat-infants-spinal-muscular-atrophy
[2] Novartis. (2022). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information.
[3] IQVIA. (2022). Global gene therapy market report.
[4] CMS. (2022). Medicare reimbursement policies for gene therapies.
[5] GlobalData. (2023). Gene therapy market outlook and pricing trends.
